摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

phenyl (3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)carbamate | 1414580-48-5

中文名称
——
中文别名
——
英文名称
phenyl (3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)carbamate
英文别名
phenyl 3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-ylcarbamate;phenyl N-(5-ethoxy-4-methyl-2-phenylpyrazol-3-yl)carbamate
phenyl (3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)carbamate化学式
CAS
1414580-48-5
化学式
C19H19N3O3
mdl
——
分子量
337.378
InChiKey
QPAGAIUKJYSXOL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    25
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.16
  • 拓扑面积:
    65.4
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    phenyl (3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)carbamate 、 (2-cyclopropyl-5-(methoxymethyl)phenyl)methanamine 在 N,N-二异丙基乙胺 作用下, 以 1,2-二氯乙烷 为溶剂, 以33%的产率得到1-(2-cyclopropyl-5-(methoxymethyl)benzyl)-3-(3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)urea
    参考文献:
    名称:
    [EN] N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
    [FR] COMPOSÉS DE N-(ARYLALKYLE)-N'-PYRAZOLYLE-URÉE, DE THIOURÉE, DE GUANIDINE ET DE CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
    摘要:
    公式I的化合物或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药,其中环A、环C、X、Ra、Rb、Rc、Rd和n如本文所述定义,是TrkA激酶的抑制剂,可用于治疗可以用TrkA激酶抑制剂治疗的疾病,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或骨盆疼痛综合征。
    公开号:
    WO2014078331A1
  • 作为产物:
    描述:
    苯肼potassium carbonate 、 sodium hydroxide 作用下, 以 1,4-二氧六环乙酸乙酯N,N-二甲基甲酰胺 为溶剂, 反应 51.0h, 生成 phenyl (3-ethoxy-4-methyl-1-phenyl-1H-pyrazol-5-yl)carbamate
    参考文献:
    名称:
    [EN] BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
    [FR] COMPOSÉS D'HÉTÉROARYLE URÉE, THIOURÉE,GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
    摘要:
    式I化合物或其立体异构体、互变异构体或药学上可接受的盐、溶剂合物或前药,其中环A、环C和X如本文所定义,是TrkA激酶的抑制剂,并且在治疗可以用TrkA激酶抑制剂治疗的疾病中具有用处,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。
    公开号:
    WO2014078408A1
点击查看最新优质反应信息

文献信息

  • [EN] BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS DE THIO-URÉE, GUANIDINE, CYNOGUANIDINE ET D'URÉE BICYCLIQUES UTILES POUR LE TRAITEMENT DE LA DOULEUR
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2014078454A1
    公开(公告)日:2014-05-22
    Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
    公式I的化合物:或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药,其中环A、环C和X如本文定义,是TrkA激酶的抑制剂,可用于治疗可以用TrkA激酶抑制剂治疗的疾病,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病、前列腺炎和盆腔疼痛综合症。
  • PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
    申请人:Allen Shelley
    公开号:US20150166564A1
    公开(公告)日:2015-06-18
    Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R 1 , R 2 , R a , R b , R c , R d , X, Y, B, and Ring C are as defined herein, and wherein the Y—B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    化合物I的公式:或其立体异构体、互变异构体、药学上可接受的盐、溶剂或前药,其中R1、R2、Ra、Rb、Rc、Rd、X、Y、B和环C的定义如本文所述,其中Y-B基团和NH-C(═X)-NH基团处于反式构象,是TrkA激酶的抑制剂,可用于治疗可以通过TrkA激酶抑制剂治疗的疾病,例如疼痛、癌症、炎症、神经退行性疾病和某些传染病。
  • N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
    申请人:ARRAY BIOPHARMA INC.
    公开号:US20160272592A1
    公开(公告)日:2016-09-22
    Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
    式I的化合物或其立体异构体、互变异构体、药学上可接受的盐、溶剂化合物或前药,其中环A、环C、X、Ra、Rb、Rc、Rd和n的定义如本文所述,是TrkA激酶的抑制剂,可用于治疗可通过TrkA激酶抑制剂治疗的疾病,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、Sjogren综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或盆腔疼痛综合征。
  • Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors
    申请人:Array BioPharma Inc.
    公开号:US10323022B2
    公开(公告)日:2019-06-18
    Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and Ring C are as defined herein, and wherein the Y—B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    式 I 的化合物: 或其立体异构体、同系物、或其药学上可接受的盐、或其溶剂或原药,其中 R1、R2、Ra、Rb、Rc、Rd、X、Y、B 和环 C 如本文所定义,且其中 Y-B 分子和 NH-C(═X)-NH 分子为反式构型、是 TrkA 激酶的抑制剂,可用于治疗可使用 TrkA 激酶抑制剂治疗的疾病,如疼痛、癌症、炎症、神经退行性疾病和某些传染性疾病。
  • Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
    申请人:Array BioPharma Inc.
    公开号:US10351575B2
    公开(公告)日:2019-07-16
    Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
    式 I 的化合物或其立体异构体、同系物或药学上可接受的盐、溶液剂或原药,其中环 A、环 C 和 X 如本文所定义,是 TrkA 激酶的抑制剂,可用于治疗可使用 TrkA 激酶抑制剂治疗的疾病,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染性疾病、Sjogren 综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。
查看更多